Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.56 |
| ▸ | CCR2 | P41597 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 5/20 | 0.55 |
| ▸ | ACHE | P22303 | 5/20 | 0.55 |
| ▸ | BACE1 | P56817 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551073 | 1.00 | ROCK1 (0.56) | ROCK1ROCK2CCR2BCHEACHE | |
| SCHEMBL3546613 | 0.93 | ACHE (0.60) | BCHEACHEBACE1FAAH | |
| SCHEMBL27720300 | 0.89 | HRH3 (0.54) | KCNH2 | |
| SCHEMBL3545728 | 0.85 | HRH3 (0.62) | BCHEACHEBACE1FAAH | |
| SCHEMBL9598403 | 0.85 | ROCK1 (0.65) | ROCK1ROCK2CCR2BCHEKCNH2 | |
| SCHEMBL6181435 | 0.83 | ALDH1A1 (0.49) | ACHEKCNH2 | |
| SCHEMBL9235807 | 0.82 | HRH3 (0.61) | KCNH2 | |
| SCHEMBL11729293 | 0.82 | ROCK1 (0.61) | ROCK1ROCK2CCR2BCHEKCNH2 | |
| SCHEMBL27573482 | 0.81 | MGLL (0.48) | CCR2BCHEACHEBACE1 | |
| SCHEMBL12478315 | 0.81 | CCR2 (0.52) | ROCK1ROCK2CCR2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1795192-A2 | 1-Substituted imidazole derivatives as nos inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-7202263-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-10 | — | — | US | disclosed |
| EP-1501504-B1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-6982259-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-01-03 | — | — | US | disclosed |
| EP-1501504-A1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2003092678-A1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | ROCK1 579/4885ROCK2 1519/4885CCR2 4137/4885 |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | ROCK1 394/4885ROCK2 898/4885CCR2 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.